journal
MENU ▼
Read by QxMD icon Read
search

Recent Patents on Anti-infective Drug Discovery

journal
https://www.readbyqxmd.com/read/29769010/evaluation-of-fosfomycin-activity-against-esbl-producing-enterobacteriaceae-isolated-from-iran
#1
Hossein Kazemian
BACKGROUND: Rising rates of antimicrobial resistance among Enterobacteriaceae limit the use of reliably active forms of available drugs. The aim of this study was to investigate the prevalence of fosfomycin (US6794490B2) resistance gene among ESBL producing isolates in Iran. METHOD: We tested 355 isolates of Enterobacteriacea collected from various clinical samples including urine, wounds, blood and other sources during June 2016 to July 2017. Antibiotic sensitivity and extended spectrum beta lactamase (ESBL) production were tested using agar dilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines...
May 16, 2018: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/29701161/ferula-gummosa-boiss-inhibits-multi-drug-resistant-clinical-pseudomonas-aeruginosas
#2
Fereshteh Satarian, Hamideh Mahmoodzadeh Hosseini, Abdolamir Ghadaksaz, Mohsen Amin, Abbas Ali Imani Fooladi
BACKGROUND: Multi-drug resistance among Pseudomonas aeruginosa (P. aeruginosa) clinical isolates is increasing and becoming a serious problem for public health authorities worldwide. OBJECTIVE: The aim of current study is the introducing a potent antibacterial compound against the resistant P. aeruginosa. The recent patents on antimicrobial properties of extracts drived from Apiaceae family plants (WO2017216602A1, KR20050054247A and KR100285781B1) were used to to assess other member Ferula gummosa (F...
April 26, 2018: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/29219058/macrophage-targeted-cellular-carriers-for-effective-delivery-of-anti-tubercular-drugs
#3
S Beg, Jaya Agnihotri, Shibhna Singh, Mohammad Wais
Newly developed vaccine VPM1002 confers paradigm swing in the prophylactic treatment of tuberculosis (TB).Multi drug resistant and latent TB in adults as well as in underprivileged patients is instigating menace over world population if the host is immune-compromised. One third of the world's population is infected with TB. Recently it is estimated around 9.6 million people around the world became sick with TB disease. There were 1.5 million TB-related deaths worldwide. Therefore with the advent in biotechnology and Nano engineering, newly adapted survival molecular mechanism of Mycobacterium tuberculosis, new targets receptors on alveolar macrophages must be explored out for eradication of TB from the globe...
December 7, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/29119936/recent-patents-on-light-based-anti-infective-approaches
#4
Imran Ahmed, Yanyan Fang, Min Lu, Quan Yan, Ahmed Mohamed Kamel El-Hussein, Michael R Hamblin, Tianhong Dai
BACKGROUND: Antibiotic resistance is one of the most serious health threats to modern medicine. The lack of potent antibiotics puts us at a disadvantage in the fight against infectious diseases, especially those caused by antibiotic-resistant microbial strains. To this end, an urgent need to search for alternative antimicrobial approaches has arisen. In the last decade, light-based therapy has made significant strides in this fight to combat antibiotic resistance among various microbial strains...
November 7, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28990540/current-progress-in-synthesis-characterization-and-applications-of-silver-nanoparticles-precepts-and-prospects
#5
Abul Barkat, Harshita, Sarwar Beg, Javed Naim, Faheem H. Pottoo, Satya P. Singh, Farhan J. Ahmad
Background: Silver nanoparticles (AgNPs), are amongst the utmost striking na-nosized materials that are extensively applied in a variety of biomedical applications which includes diagnostic use, disease management, medical device coating, drug delivery and for personal health care. Discussion: With the growing interest and its application in the health care sector, it is be-coming necessary for a better understanding and exploration of AgNPs mechanism of ac-tion like biological interaction, their possible toxicity, and safety concern to human expo-sure...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28990539/new-drugs-and-vaccines-for-tuberculosis
#6
S Beg, Praveen Gaur, Shikha Mishra
Tuberculosis (TB) is an infectious disease that resulted in estimated 9.6 million new cases in 2014 and 1.5 million deaths. The available drug regimen for TB is time consuming which more often leads to the patient non compliance which then results in occurrence of drug resistant TB (Multi-drug and extremely drug resistant TB) in several portions of the world. The dangerous combinations of TB and HIV is taking its toll on human health. The foremost factor is non- profit associated with the development of anti TB drugs...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28990538/recent-complications-and-issues-in-tuberculosis-treatment
#7
Mohamad Taleuzzaman, Vinay K Patel
BACKGROUND: Tuberculosis is a one of the major communicable disease which can be preventable and curable. Even though the prevalence of tuberculosis infection is more even though this disease causes major morbidity and mortality. [3] To determine association between tuberculosis (TB) related stigma and delay in seeking a treatment after the onset of symptoms associated with tuberculosis. METHODS: Physicians conducted the interviews using a structured questionnaire...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28990537/nanomedicine-for-the-treatment-of-tuberculosis
#8
Zabih Ullah, Md Tanwir Athar, Abdus Samad
BACKGROUND: The diseases tuberculosis, triggered by intracellular pathogens, is a major problem for the global medical professionals. Treatments for these diseases through conventional dosage form consist of long-term therapy with multiple drugs leads to several side effects and contribute to low patient compliance and drug resistance. METHODS: The pathogens are fond to be situated in the intracellular compartments of the cells, which ultimately results in additional blockades to effective treatment...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28625141/bedaquiline-a-new-hope-for-shorter-and-better-anti-tuberculosis-regimens
#9
Niccolò Riccardi, Filippo Del Puente, Federica Magnè, Lucia Taramasso, Antonio Di Biagio
Background: In 2014, an estimated 1.8 million people died from Mycobacterium tuberculosis (MTB); moreover, 680,000 people developed multidrug-resistant TB (MDR-TB). Methods: Currently available anti-MDR and XDR regimens are long-lasting and expensive, need high adherence and are undermined by a high frequency of adverse drug events, thus leading to a low success rate; moreover, in the last 50 years only two new molecules, bedaquiline (BDQ) and delamanid, have been approved and released for treatment of MDR-TB...
June 19, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28625140/recently-patented-viral-nucleotide-sequences-and-generation-of-virus-derived-vaccines
#10
Srividhya Venkataraman, Tauqeer Ahmad, Mounir AbouHaidar, Kathleen L Hefferon
With the increased comprehension of the molecular biology of viruses, there has been a recent surge in the application of virus sequences and viral gene expression strategies towards the diagnosis and treatment of diseases. The scope of the patenting landscape has widened as a result and the current review discusses patents pertaining to live / attenuated viral vaccines. The vaccines addressed here have been developed by both conventional means as well as by the state-of-the-art genetic engineering techniques...
June 19, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28571549/nanoemulsion-based-transdermal-drug-delivery-system-for-the-treatment-of-tuberculosis
#11
Mohammad Wais, Mohd Aqil, Ashish Kumar Sharma, Jaya Agnihotri
BACKGROUND: The nanoemulsion based carriers are the most suitable delivery systems for poorly soluble drugs to improve the solubility of drugs, permeation of drugs and ultimately increase bioavailability by transdermal therapeutic system. The nanoemulsion for poorly soluble drugs is the excellent and offered several advantages over others carriers. METHODS: For the nanoemulsions formulation they have to deliver the energetic element at the specific organ with nominal uneasiness...
June 1, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28480833/nanoemulsion-for-the-effective-treatment-and-management-of-anti-tubercular-drug-therapy
#12
Sarwar Beg, Sumant Saini, Sarim Imam, Mahfoozur Rahman, Suryakanta Swain, M S Hasnain
BACKGROUND: Tuberculosis is considered as one of the deadliest diseases of human existence. Since ancient age the treatment of tuberculosis has been highly challenging primarily owing to the pathogenic nature of the Mycobacterium and its diverse spots of localization in human body including lungs, liver, spleen, eye, meninges and lymph nodes. METHODS: The conventional drug therapy employed for the treatment of tuberculosis is not highly satisfactorily owing to low oral bioavailability of the drugs...
May 3, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28595544/nanocarriers-for-the-treatment-of-tuberculosis
#13
Syed Sarim Imam, Sadaf Jamal Gilani, Abdul Hafeez, Mahfoozur Rahman
BACKGROUND: Nanotechnology is an emerging science with the potential to create new materials and strategies involving manipulation of matter at the nanometer scale. Colloidal drug delivery systems have been extensively investigated as drug carriers for the application of different anti tubercular drugs. METHODS: The different delivery systems like solid lipid nanoparticles and polymeric nanoparticles have been investigated for a long time to treat diseases. There are number of drawbacks in conventional TB dosage forms are the development of multiple drug resistance, resulting intolerable toxicity and high dose requirements...
April 27, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28506204/antibiotic-effects-of-loperamide-homology-of-human-targets-of-loperamide-with-targets-in-acanthamoeba-spp
#14
Abdul Mannan Baig, Zohaib Rana, M Mohsin Mannan, S Sumayya Tariq, H R Ahmad
BACKGROUND: Loperamide is an anti-diarrheal drug prescribed for non-infectious diarrhea. The drug is an opioid receptor agonist, a blocker of voltage-dependent calcium channel (Cav) and a calmodulin (CaM) inhibitor on human cells. Loperamide has been reported to exert anti-amoebic effects against pathogenic strains of Acanthamoeba castellanii. OBJECTIVES: The precise mode of antibiotic action, cellular target homology with human counterparts and the pattern of cell death induced by loperamide in Acanthamoeba castellanii remain to be established...
April 25, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28506203/optimization-of-microemulsion-based-transdermal-gel-of-triamcinolone
#15
Bhagyashree Chaudhari, Swati Jagdale
BACKGROUND: Triamcinolone is a long acting corticosteroid used in the treatment of arthritis, eczema, psoriasis and similar conditions which causes inflammation. Triamcinolone has half-life of 88 minutes. Prolonged oral use is associated with gastrointestinal adverse effects as peptic ulcer, abdominal distention and ulcerative esophagitis. Microemulgel offers advantage of better stability, better loading capacity and controlled release especially for drug with short half life. OBJECTIVE: Objective of the present study was to optimize microemulgel based transdermal delivery of triamcinolone...
April 25, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28443511/current-approaches-and-future-prospects-of-nanomedicines-in-tuberculosis-therapy
#16
Md Tanwir Athar, Zabih Ullah
Tuberculosis (TB), which is caused by the Mycobacterium tuberculosis, is a serious threat and one of the major health problems worldwide. In recent years, an estimated of 9.6 million TB cases occurred and 1.5 million death occurred due to TB worldwide. The present review is an attempt to introduce this disease focusing on the pathophysiology of the disease, the current approachesand the related patents for treatment and the future planningfor combating this disease.
April 25, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28215171/oral-colonization-by-nosocomial-pathogens-during-hospitalization-in-intensive-care-unit-and-prevention-strategies
#17
Hossein Kazemian, Samane Bourbour, Maryam Beheshti, Abbas Bahador
BACKGROUND: Critically ill patients are very susceptible to a variety of disorders and infections during hospitalization in Intensive Care Units (ICU). Among these problems, nosocomial infections are major causes of morbidity and mortality. METHODS: Nosocomial pneumonias, specifically ventilator associated pneumonias have become a major health care issue. The implication of oral care in hospital presents challenges that can prevent or reduce the risk of nosocomial pneumonias in ICU...
February 15, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28137227/3rd-generation-of-cephalosporins-and-monobactam-resistant-among-pathogenic-bacteria-collected-from-ilam-hospitals-during-2008-to-2015-a-systematic-review-and-meta-analysis
#18
Saeed Hemati, Sobhan Ghafourian, Nourkhoda Sadeghfard, Zahra Mahdavi, Abbas Maleki, Fatemeh Sayehmiri, Kouroush Sayehmiri, Lidija Bogdanović, Morovat Taherikalani
BACKGROUND: Recently, increasing antibiotic resistance is causing serious public-health concerns worldwide. This phenomenon increased patient's morbidity and mortality rate, particularly in immunocompromised individuals. METHODS: Considering that antimicrobial resistance can vary according to geographical location, we investigated the status of antibiotic resistance in Ilam province from 2008 to 2009. RESULTS: The results of our study showed that antibiotic resistance rates to aztreonam, cefotaxime, ceftazidime and ceftriaxone were 38%, 39%, 43% and 48% respectively...
January 29, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/29745317/patent-selections
#19
(no author information available yet)
No abstract text is available yet for this article.
2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/29745316/editorial-nanomedicines-for-the-treatment-of-tuberculosis-role-of-nanocarriers-and-functional-excipients
#20
EDITORIAL
Abdus Samad, Iram Nazish, Sarwar Beg
No abstract text is available yet for this article.
2017: Recent Patents on Anti-infective Drug Discovery
journal
journal
41279
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"